Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.…
Ondine Biomedical (LSE:OBI) Advances Its Technology
Ondine Biomedical (LON: OBI) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 8.250 GBp on 20 November 2026, down 26.7% over 52 weeks. Its 52-week range is 7.500 GBp to 15.50 GBp: the price is 46.8% below the high and 10.0% above the low.
Its market capitalisation is 54.55M GBP.
Ondine Biomedical reports revenue up 22.9% year over year.
It holds more cash than debt, a net cash position of 5.05M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 29.00 GBp is 251.5% above the current price.
No upcoming events tracked.